Cancer · 2010 · 75 citations · 15 references
MedicineNuclear MedicineOncologyThoracic OncologyTreatment PlanningTumor ProgressionCancer StagingLung CancerPositron Emission TomographyRadiation TherapyRadiation Treatment PlanningTumor CharacterizationDisease Progression StagingDisease Stage AssessmentLung Cancer StagingTumor Doubling TimeTumor Growth DynamicsTumor Growth MonitoringTumor Growth RateTumor Progression Dynamics
BACKGROUND: The authors studied growth and progression of untreated nonsmall cell lung cancer (NSCLC) by comparing diagnostic and radiotherapy (RT) planning fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) scans before proposed radical chemo-RT. METHODS: Patients enrolled on a prospective clinical trial were eligible for this analysis if they underwent 2 pretreatment whole body FDG-PET/CT scans, >7 days apart. Scan 1 was performed for diagnosis/disease staging and scan 2 for RT planning. Interscan comparisons included disease stage, metabolic characteristics, tumor doubling times, and change in treatment intent. RESULTS: Eighty-two patients underwent planning PET/CT scans between October 2004 and February 2007. Of these, 28 patients (61% stage III, 18% stage II) had undergone prior staging PET/CT scans. The median interscan period was 24 days (range, 8-176 days). Interscan disease progression (TNM stage) was detected in 11 (39%) patients. The probability of upstaging within 24 days was calculated to be 32% (95% confidence interval [CI], 18%-49%). Treatment intent changed from curative to palliative in 8 (29%) cases, in 7 because of PET. For 17 patients who underwent serial PET/CT scans under standardized conditions, there was a mean relative interscan increase of 19% in tumor maximum standardized uptake value (SUV) (P=.022), 16% in average SUV (P=.004), and 116% in percentage injected dose (P=.002). Estimated doubling time of FDG avid tumor was 66 days (95% CI, 51-95 days). CONCLUSIONS: Rapid tumor progression was detected in patients with untreated, predominantly stage III, NSCLC on serial FDG-PET/CT imaging, highlighting the need for prompt diagnosis, staging, and initiation of therapy in patients who are candidates for potentially curative therapy.
15
TNM Classification of Malignant Tumors
Darryl Carter · The American Journal of Surgical Pathology · 1998 · 6.4K citations
Revisions in the International System for Staging Lung Cancer
Clifton F. Mountain · CHEST Journal · 1997 · 4.6K citations
A Gompertzian model of human breast cancer growth.
Larry Norton · PubMed · 1988 · 695 citations
Medicine, Cancer Biology, Oncology +17